Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
C. Hayton (Manchester, United Kingdom), F. Elsawy (Manchester, United Kingdom), T. Garfoot (Manchester, United Kingdom), C. Leonard (Manchester, United Kingdom), P. Rivera-Ortega (Manchester, United Kingdom), J. Blaikley (Manchester, United Kingdom), N. Chaudhuri (Manchester, United Kingdom). Safety and tolerability of immunosuppression in non-IPF ILD: clinical experience from a tertiary ILD centre.. 1728

Member's Comments

No comment yet.

Related content which might interest you: Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice Source: ERJ Open Res, 4 (4) 00049-2018; 10.1183/23120541.00049-2018 Year: 2018 Efficacy and safety of pirfenidone in patients with IPF. A single center real-life experience. Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 Clinical experience with nintedanib for IPF in 3 UK tertiary referral centres Source: International Congress 2016 – IPF treatment II Year: 2016 Late Breaking Abstract - Effectiveness and tolerability of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) from a large Italian practice cohort Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias Year: 2018 Safety and efficacy of sputum induction in COPD patients Source: Annual Congress 2013 –Respiratory nursing care: assessment, interventions and education Year: 2013 Clinical experience with Nintedanib for treatment of idiopathic pulmonary fibrosis (IPF) in Spain. Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 All-case post-marketing surveillance (PMS) of pirfenidone in Japan: Clinical characteristics, efficacy and safety profile in >1300 patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Clinical and functional effectiveness of roflumilast in severe COPD patients Source: Annual Congress 2013 –Modern approach to various clinical settings Year: 2013 Safety and tolerability of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) receiving commonly used concomitant medications Source: Annual Congress 2012 - Diffuse parenchymal lung disease: clinical profiles and collagen vascular disease Year: 2012 Acute exacerbation of ILD: an Indian tertiary centre experience Source: International Congress 2018 – Clinical aspects of hypersensitivity pneumonitis (HP) and CTD-ILD: diagnosis, monitoring and treatment Year: 2018 Pulmonary rehabilitation in patients with group 3 pulmonary hypertension: evaluation of clinical outcomes, adherence and safety. Source: International Congress 2019 – The future of pulmonary rehabilitation discussed today Year: 2019 Real-life experience with pirfenidone in idiopathic pulmonary fibrosis (IPF) in a single centre in Italy. A retrospective study. Source: International Congress 2017 – IPF: from the bench to the bedside Year: 2017 PROOF: A prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting in Belgium and Luxembourg: Exposure in the interim report of 175 IPF patients Source: International Congress 2016 – IPF clinical Year: 2016 The outcome of patients with COPD admitted to UK hospitals with an exacerbation. Results from the RCP/BTS national COPD audit Source: Annual Congress 2005 - COPD - acute exacerbations Year: 2005 Exacerbations, hospitalisations and mortality in patients with idiopathic pulmonary fibrosis in clinical practice: INSIGHTS-IPF registry Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): clinical problems Year: 2017 Clinical and inflammatory characteristics of patients with COPD in primary care: an observational study Source: International Congress 2017 – Markers of COPD progression Year: 2017 The feasibility, efficacy and safety of a multidisciplinary care pathway for in-patient treatment of acute exacerbation of bronchiectasis Source: International Congress 2015 – Latest insights into chronic care Year: 2015 Safety and tolerability of nintedanib in patients with fibrosing interstitial lung diseases: pooled data from four trials Source: Virtual Congress 2021 – Interstitial lung disease, COVID-19 and friends Year: 2021 Long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis of 4 clinical trials Source: International Congress 2016 – IPF treatment I Year: 2016 Efficacy and safety of etanercept in patients with idiopathic pulmonary fibrosis (IPF) Source: Eur Respir J 2006; 28: Suppl. 50, 767s Year: 2006